JP5723156B2 - 食道腺癌の診断及び治療のための方法及び組成物 - Google Patents
食道腺癌の診断及び治療のための方法及び組成物 Download PDFInfo
- Publication number
- JP5723156B2 JP5723156B2 JP2010529072A JP2010529072A JP5723156B2 JP 5723156 B2 JP5723156 B2 JP 5723156B2 JP 2010529072 A JP2010529072 A JP 2010529072A JP 2010529072 A JP2010529072 A JP 2010529072A JP 5723156 B2 JP5723156 B2 JP 5723156B2
- Authority
- JP
- Japan
- Prior art keywords
- expression
- mir
- tissue
- sample
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 142
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 title claims description 41
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 title claims description 41
- 208000028653 esophageal adenocarcinoma Diseases 0.000 title claims description 41
- 238000011282 treatment Methods 0.000 title description 21
- 238000003745 diagnosis Methods 0.000 title description 10
- 239000000203 mixture Substances 0.000 title description 7
- 230000014509 gene expression Effects 0.000 claims description 317
- 206010028980 Neoplasm Diseases 0.000 claims description 116
- 239000000090 biomarker Substances 0.000 claims description 89
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 77
- 208000023514 Barrett esophagus Diseases 0.000 claims description 74
- 208000023665 Barrett oesophagus Diseases 0.000 claims description 74
- 238000004393 prognosis Methods 0.000 claims description 32
- 108091093189 Mir-375 Proteins 0.000 claims description 20
- 230000002829 reductive effect Effects 0.000 claims description 17
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 13
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 230000001575 pathological effect Effects 0.000 claims description 10
- 238000010837 poor prognosis Methods 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 6
- 108091070501 miRNA Proteins 0.000 description 196
- 108090000623 proteins and genes Proteins 0.000 description 195
- 239000000523 sample Substances 0.000 description 147
- 210000001519 tissue Anatomy 0.000 description 145
- 239000000047 product Substances 0.000 description 143
- 239000002679 microRNA Substances 0.000 description 134
- 210000004027 cell Anatomy 0.000 description 129
- 201000011510 cancer Diseases 0.000 description 88
- 150000007523 nucleic acids Chemical class 0.000 description 75
- 208000009956 adenocarcinoma Diseases 0.000 description 60
- 102000039446 nucleic acids Human genes 0.000 description 55
- 108020004707 nucleic acids Proteins 0.000 description 55
- 230000004083 survival effect Effects 0.000 description 54
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 52
- 150000001875 compounds Chemical class 0.000 description 45
- 238000002493 microarray Methods 0.000 description 45
- 239000003795 chemical substances by application Substances 0.000 description 43
- 201000010099 disease Diseases 0.000 description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 43
- 238000012360 testing method Methods 0.000 description 38
- 230000002401 inhibitory effect Effects 0.000 description 37
- 239000002502 liposome Substances 0.000 description 32
- 230000001965 increasing effect Effects 0.000 description 29
- 108091062762 miR-21 stem-loop Proteins 0.000 description 29
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 29
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 29
- 238000009396 hybridization Methods 0.000 description 28
- 239000002773 nucleotide Substances 0.000 description 28
- 125000003729 nucleotide group Chemical group 0.000 description 28
- 238000011529 RT qPCR Methods 0.000 description 24
- 108020004459 Small interfering RNA Proteins 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 21
- 108020004999 messenger RNA Proteins 0.000 description 21
- 108700011259 MicroRNAs Proteins 0.000 description 19
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000008859 change Effects 0.000 description 17
- 230000000295 complement effect Effects 0.000 description 17
- 239000013068 control sample Substances 0.000 description 17
- 239000013603 viral vector Substances 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 108091033773 MiR-155 Proteins 0.000 description 16
- 230000003247 decreasing effect Effects 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- 108091028141 MiR-203 Proteins 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 230000000692 anti-sense effect Effects 0.000 description 14
- 238000012549 training Methods 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 201000004101 esophageal cancer Diseases 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000011127 radiochemotherapy Methods 0.000 description 13
- 238000010200 validation analysis Methods 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 12
- 230000007774 longterm Effects 0.000 description 12
- 230000014207 opsonization Effects 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 108091043612 miR-146b stem-loop Proteins 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 108091054642 miR-194 stem-loop Proteins 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 238000001574 biopsy Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 108091043222 miR-181b stem-loop Proteins 0.000 description 8
- 108091086416 miR-192 stem-loop Proteins 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 238000009739 binding Methods 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 238000007901 in situ hybridization Methods 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 108091062154 Mir-205 Proteins 0.000 description 6
- 108091062140 Mir-223 Proteins 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000005907 cancer growth Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000003499 nucleic acid array Methods 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 6
- 229920001451 polypropylene glycol Polymers 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 239000013607 AAV vector Substances 0.000 description 5
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 108091080933 Mir-192/215 microRNA precursor Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 201000005619 esophageal carcinoma Diseases 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108091088730 miR-215 stem-loop Proteins 0.000 description 5
- 238000010208 microarray analysis Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 108091007772 MIRLET7C Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108091028695 MiR-224 Proteins 0.000 description 4
- 108091027766 Mir-143 Proteins 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 108091023663 let-7 stem-loop Proteins 0.000 description 4
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 4
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108091032320 miR-146 stem-loop Proteins 0.000 description 4
- 108091024530 miR-146a stem-loop Proteins 0.000 description 4
- -1 mir-220 Proteins 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 108091007428 primary miRNA Proteins 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 125000002652 ribonucleotide group Chemical group 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 230000000153 supplemental effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 208000025760 Benign familial haematuria Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 206010067671 Disease complication Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 108020004518 RNA Probes Proteins 0.000 description 3
- 239000003391 RNA probe Substances 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000011256 aggressive treatment Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 108091037473 miR-103 stem-loop Proteins 0.000 description 3
- 108091027943 miR-16 stem-loop Proteins 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 102000008682 Argonaute Proteins Human genes 0.000 description 2
- 108010088141 Argonaute Proteins Proteins 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 108091007774 MIR107 Proteins 0.000 description 2
- 108091008065 MIR21 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 2
- 108091028684 Mir-145 Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010043958 Peptoids Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101150099493 STAT3 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000906446 Theraps Species 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000007321 biological mechanism Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 108091091807 let-7a stem-loop Proteins 0.000 description 2
- 108091057746 let-7a-4 stem-loop Proteins 0.000 description 2
- 108091028376 let-7a-5 stem-loop Proteins 0.000 description 2
- 108091024393 let-7a-6 stem-loop Proteins 0.000 description 2
- 108091091174 let-7a-7 stem-loop Proteins 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 108091050539 miR-107 stem-loop Proteins 0.000 description 2
- 108091079012 miR-133a Proteins 0.000 description 2
- 108091024038 miR-133a stem-loop Proteins 0.000 description 2
- 108091045872 miR-135 stem-loop Proteins 0.000 description 2
- 108091026523 miR-135a stem-loop Proteins 0.000 description 2
- 108091031103 miR-181a stem-loop Proteins 0.000 description 2
- 108091046591 miR-181a-4 stem-loop Proteins 0.000 description 2
- 108091049627 miR-181a-5 stem-loop Proteins 0.000 description 2
- 108091048308 miR-210 stem-loop Proteins 0.000 description 2
- 108091063344 miR-30b stem-loop Proteins 0.000 description 2
- 108091055059 miR-30c stem-loop Proteins 0.000 description 2
- 108091023818 miR-7 stem-loop Proteins 0.000 description 2
- 108091024443 miRa-135-1 stem-loop Proteins 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920001542 oligosaccharide Chemical class 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- 239000000092 prognostic biomarker Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000029862 Barrett adenocarcinoma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- RGHNJXZEOKUKBD-MBMOQRBOSA-N D-mannonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-MBMOQRBOSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000974349 Homo sapiens Nuclear receptor coactivator 6 Proteins 0.000 description 1
- 101000611943 Homo sapiens Programmed cell death protein 4 Proteins 0.000 description 1
- 101000854388 Homo sapiens Ribonuclease 3 Proteins 0.000 description 1
- 101000801701 Homo sapiens Tropomyosin alpha-1 chain Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108091033433 MiR-191 Proteins 0.000 description 1
- 108091028066 Mir-126 Proteins 0.000 description 1
- 108091060302 Mir-320 Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100022929 Nuclear receptor coactivator 6 Human genes 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102100040992 Programmed cell death protein 4 Human genes 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 108020005093 RNA Precursors Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 102100036007 Ribonuclease 3 Human genes 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- MMXKIWIWQPKTIK-KPRKPIBOSA-N [(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl [(2r,3s,5r)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)[C@@H](O)C1 MMXKIWIWQPKTIK-KPRKPIBOSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 108700021042 biotin binding protein Proteins 0.000 description 1
- 102000043871 biotin binding protein Human genes 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- BHRQIJRLOVHRKH-UHFFFAOYSA-L calcium;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;hydron Chemical compound [Ca+2].OC(=O)CN(CC(O)=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O BHRQIJRLOVHRKH-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004743 esophageal carcinogenesis Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- 150000002270 gangliosides Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 108091053410 let-7 family Proteins 0.000 description 1
- 108091007423 let-7b Proteins 0.000 description 1
- 108091033753 let-7d stem-loop Proteins 0.000 description 1
- 108091042844 let-7i stem-loop Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108091053735 lin-4 stem-loop Proteins 0.000 description 1
- 108091032363 lin-4-1 stem-loop Proteins 0.000 description 1
- 108091028008 lin-4-2 stem-loop Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 108091028606 miR-1 stem-loop Proteins 0.000 description 1
- 108091026501 miR-122a stem-loop Proteins 0.000 description 1
- 108091044988 miR-125a stem-loop Proteins 0.000 description 1
- 108091049513 miR-125a-1 stem-loop Proteins 0.000 description 1
- 108091040046 miR-125a-2 stem-loop Proteins 0.000 description 1
- 108091091360 miR-125b stem-loop Proteins 0.000 description 1
- 108091057645 miR-15 stem-loop Proteins 0.000 description 1
- 108091091751 miR-17 stem-loop Proteins 0.000 description 1
- 108091069239 miR-17-2 stem-loop Proteins 0.000 description 1
- 108091055042 miR-181 stem-loop Proteins 0.000 description 1
- 108091063348 miR-193 stem-loop Proteins 0.000 description 1
- 108091036762 miR-193a stem-loop Proteins 0.000 description 1
- 108091089775 miR-200b stem-loop Proteins 0.000 description 1
- 108091045665 miR-202 stem-loop Proteins 0.000 description 1
- 108091039792 miR-20b stem-loop Proteins 0.000 description 1
- 108091055878 miR-20b-1 stem-loop Proteins 0.000 description 1
- 108091027746 miR-20b-2 stem-loop Proteins 0.000 description 1
- 108091047189 miR-29c stem-loop Proteins 0.000 description 1
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 description 1
- 108091027983 miR-378-1 stem-loop Proteins 0.000 description 1
- 108091089716 miR-378-2 stem-loop Proteins 0.000 description 1
- 108091056170 miR-499 stem-loop Proteins 0.000 description 1
- 108091050885 miR-499-1 stem-loop Proteins 0.000 description 1
- 108091038523 miR-499-2 stem-loop Proteins 0.000 description 1
- 108091030520 miR-7-2 stem-loop Proteins 0.000 description 1
- 108091059456 miR-92-1 stem-loop Proteins 0.000 description 1
- 108091084336 miR-92-2 stem-loop Proteins 0.000 description 1
- 108091032902 miR-93 stem-loop Proteins 0.000 description 1
- 108091076732 miR-99a stem-loop Proteins 0.000 description 1
- 108091064318 miR-99a-1 stem-loop Proteins 0.000 description 1
- 108091086202 miR-99a-2 stem-loop Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000000088 plastic resin Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 229940073585 tromethamine hydrochloride Drugs 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97930007P | 2007-10-11 | 2007-10-11 | |
| US60/979,300 | 2007-10-11 | ||
| PCT/US2008/079482 WO2009049129A1 (en) | 2007-10-11 | 2008-10-10 | Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011501943A JP2011501943A (ja) | 2011-01-20 |
| JP2011501943A5 JP2011501943A5 (enExample) | 2011-12-01 |
| JP5723156B2 true JP5723156B2 (ja) | 2015-05-27 |
Family
ID=40549579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529072A Expired - Fee Related JP5723156B2 (ja) | 2007-10-11 | 2008-10-10 | 食道腺癌の診断及び治療のための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100285471A1 (enExample) |
| EP (1) | EP2212440A4 (enExample) |
| JP (1) | JP5723156B2 (enExample) |
| CN (2) | CN101861401B (enExample) |
| AU (1) | AU2008310704B2 (enExample) |
| CA (1) | CA2702241A1 (enExample) |
| WO (1) | WO2009049129A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103866018B (zh) | 2005-08-01 | 2016-05-25 | 俄亥俄州立大学研究基金会 | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 |
| CN103028120B (zh) | 2005-09-12 | 2015-08-12 | 俄亥俄州立大学研究基金会 | 用于诊断或治疗bcl2相关癌症的组合物和方法 |
| ES2524018T3 (es) | 2006-01-05 | 2014-12-03 | The Ohio State University Research Foundation | Anomalías de la expresión de microARN en tumores pancreáticos endocrinos y acinares |
| WO2007081720A2 (en) | 2006-01-05 | 2007-07-19 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
| EP2487260B1 (en) | 2006-01-05 | 2015-07-08 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of solid cancers |
| EP2369012A1 (en) | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Micro-RNA fingerprints during human megakaryocytopoiesis |
| CA2657030A1 (en) | 2006-07-13 | 2008-01-17 | The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio | Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases |
| US8071292B2 (en) | 2006-09-19 | 2011-12-06 | The Ohio State University Research Foundation | Leukemia diagnostic methods |
| JP5501766B2 (ja) | 2006-11-01 | 2014-05-28 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン |
| US8034560B2 (en) | 2007-01-31 | 2011-10-11 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML) |
| CA2690144A1 (en) | 2007-06-08 | 2008-12-18 | The Government Of The United States Of America As Represented By The Sec Retary Of Department Of Health And Human Services | Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells |
| US8053186B2 (en) | 2007-06-15 | 2011-11-08 | The Ohio State University Research Foundation | Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing |
| ES2496172T3 (es) | 2007-07-31 | 2014-09-18 | The Ohio State University Research Foundation | Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B |
| AU2008283997B2 (en) | 2007-08-03 | 2014-04-10 | The Ohio State University Research Foundation | Ultraconserved regions encoding ncRNAs |
| CN101836112A (zh) | 2007-08-22 | 2010-09-15 | 俄亥俄州立大学研究基金会 | 用于在人急性白血病中诱导epha7和erk磷酸化的脱调节的方法和组合物 |
| CA2703707A1 (en) | 2007-10-26 | 2009-04-30 | The Ohio State University Research Foundation | Methods for identifying fragile histidine triad (fhit) interaction and uses thereof |
| CN101878313A (zh) * | 2007-10-30 | 2010-11-03 | 维里德克斯有限责任公司 | 预测鳞状细胞肺癌的方法 |
| AU2009257410B2 (en) | 2008-06-11 | 2014-03-06 | Fudan University | Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy |
| TWI394839B (zh) | 2008-10-27 | 2013-05-01 | Qiagen Gaithersburg Inc | 快速結果雜交捕捉法及系統 |
| WO2010102226A1 (en) * | 2009-03-05 | 2010-09-10 | Brown University | Methods of diagnosing and treating carcinomas |
| EP2283846A1 (en) * | 2009-08-12 | 2011-02-16 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | miRNA compounds for treatment of prostate carcinoma |
| JP5960060B2 (ja) | 2009-11-23 | 2016-08-02 | ジ・オハイオ・ステート・ユニバーシティ | 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法 |
| WO2012065049A1 (en) | 2010-11-12 | 2012-05-18 | The Ohio State University Research Foundation | Materials and methods related to microrna-21, mismatch repair, and colorectal cancer |
| CA2817982C (en) | 2010-11-15 | 2020-06-30 | The Regents Of The University Of Michigan | Controlled release mucoadhesive systems |
| US8664192B2 (en) | 2011-03-07 | 2014-03-04 | The Ohio State University | Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer |
| US20140031258A1 (en) * | 2011-03-28 | 2014-01-30 | The Johns Hopkins University | Serum-based mirna microarray and its use in diagnosis and treatment of barrett's esophagus (be) and esophageal adenocarcinoma (eac) |
| WO2013033165A2 (en) * | 2011-08-29 | 2013-03-07 | University Of Miami | Compositions, kits and methods for treating obesity, diabetes and hyperglycemia |
| WO2013029116A1 (en) * | 2011-08-31 | 2013-03-07 | Monash University | Method for predicting treatment responsiveness |
| US20130078632A1 (en) * | 2011-09-23 | 2013-03-28 | Academisch Medisch Centrum | Materials and methods for prognosis of progression of barrett's esophagus |
| EP2766500A4 (en) | 2011-10-14 | 2015-10-14 | Univ Ohio State | METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER |
| WO2013066678A1 (en) * | 2011-10-26 | 2013-05-10 | Georgetown University | Microrna expression profiling of thyroid cancer |
| CA2858382A1 (en) * | 2011-12-10 | 2013-06-13 | Ohio State Innovation Foundation | Mirnas useful to reduce lung cancer tumorigenesis and chemotherapy resistance and related compositons and methods |
| CN104619353A (zh) | 2011-12-13 | 2015-05-13 | 俄亥俄州国家创新基金会 | 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移 |
| JP2015511121A (ja) | 2012-01-20 | 2015-04-16 | ジ・オハイオ・ステート・ユニバーシティ | 浸潤性および予後に関する乳がんバイオマーカーシグネチャー |
| KR101445560B1 (ko) * | 2012-05-10 | 2014-09-29 | 한국수력원자력 주식회사 | 저준위 전리방사선에 민감한 유전자 검출 방법 및 상기 방법으로 검출된 유전자 |
| WO2014100216A1 (en) * | 2012-12-19 | 2014-06-26 | The Regents Of The University Of California | Cancer-Associated MicroRNAs and Related Antibodies |
| GB201303078D0 (en) * | 2013-02-21 | 2013-04-10 | Cambridge Entpr Ltd | Methods |
| AU2014268417A1 (en) * | 2013-05-23 | 2015-11-26 | Iphenotype Llc | Methods and systems for assisting persons, product providers and/or service providers |
| US10323067B2 (en) | 2014-05-14 | 2019-06-18 | Evorx Technologies, Inc. | Methods and compositions for controlling gene expression and treating cancer |
| CN111910002B (zh) * | 2014-06-18 | 2024-04-12 | 东丽株式会社 | 食道癌的检测试剂盒或装置以及检测方法 |
| CN105368822A (zh) * | 2014-08-29 | 2016-03-02 | 香港大学 | 一种miRNA标记物、其方法和应用 |
| CN104774929B (zh) * | 2015-03-18 | 2017-06-30 | 中山大学肿瘤防治中心 | miR‑455‑3p在食管鳞状细胞癌中的诊断、治疗和预后的应用 |
| KR101657033B1 (ko) * | 2016-03-25 | 2016-09-13 | 성균관대학교산학협력단 | V-ATPase subunit V1E1의 단백질 발현 수준을 측정하여 식도암 환자의 생존율과 예후를 예측하는 방법 |
| CN106177994A (zh) * | 2016-07-18 | 2016-12-07 | 浙江大学 | miR‑1在制备治疗胃癌和乳腺癌药物中的应用 |
| KR20190077309A (ko) * | 2016-08-04 | 2019-07-03 | 베일러 리서치 인스티튜트 | 식도암 진단 및 치료 방법 |
| CN106119392B (zh) * | 2016-08-25 | 2019-12-31 | 朱伟 | 一种与食管鳞癌辅助诊断相关的血清miRNA标志物及其应用 |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| CN108103201B (zh) * | 2018-03-05 | 2022-03-01 | 江苏为真生物医药技术股份有限公司 | 外泌体microRNA分子标志物的应用及用于诊断食管癌的试剂盒 |
| CN108828229B (zh) * | 2018-06-15 | 2021-03-16 | 深圳华大生命科学研究院 | 食管癌肿瘤标志物组合及其应用 |
| CN109633156B (zh) * | 2018-12-19 | 2022-02-22 | 湖南中南大学湘雅口腔医院 | 生物标志物在评估口腔鳞癌危险程度中的应用 |
| CN109825596B (zh) * | 2019-04-19 | 2022-03-15 | 中国医学科学院肿瘤医院 | 食管癌样本的内参miRNA及其应用 |
| CN113151455B (zh) * | 2020-01-22 | 2023-04-21 | 中国药科大学 | 外泌体miR-181b-5p在食管鳞癌诊断和治疗中的应用 |
| JPWO2021162065A1 (enExample) * | 2020-02-10 | 2021-08-19 | ||
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
| CN111778339B (zh) * | 2020-08-16 | 2021-01-15 | 徐州医科大学 | 与食管癌相关的miRNA标志物及其应用 |
| CN113736886A (zh) * | 2021-09-14 | 2021-12-03 | 河北医科大学第四医院 | 用于食管癌诊断的生物标志物及其应用 |
| WO2023069510A1 (en) * | 2021-10-19 | 2023-04-27 | The United States Government As Represented By The Department Of Veterans Affairs | Cannabinoid compositions for gastroesophageal disorders |
| CN113969318A (zh) * | 2021-11-10 | 2022-01-25 | 广东省人民医院 | 组合的焦亡相关基因在食管腺癌预后模型中的应用 |
| CN116121377A (zh) * | 2022-11-01 | 2023-05-16 | 山西医科大学 | 一种食管鳞癌外泌体富含的miRNA作为诊断食管鳞癌的标志物中的应用 |
| CN118957067B (zh) * | 2024-08-12 | 2025-03-18 | 西北大学 | 一种胸部肿瘤诊断标志物cpd及其相关诊断产品和应用 |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5015568A (en) * | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
| US5202429A (en) * | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| ATE120497T1 (de) | 1988-05-09 | 1995-04-15 | Univ Temple | Verfahren zur voraussage der wirksamkeit einer antineoplastichen behandlung bei einzelnen patienten. |
| US5198338A (en) * | 1989-05-31 | 1993-03-30 | Temple University | Molecular probing for human t-cell leukemia and lymphoma |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| US6040140A (en) * | 1991-12-11 | 2000-03-21 | Thomas Jefferson University | Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities |
| US5633135A (en) * | 1991-12-11 | 1997-05-27 | Thomas Jefferson University | Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities |
| WO1993012136A1 (en) * | 1991-12-11 | 1993-06-24 | Thomas Jefferson University | Detection and treatment of acute leukemias resulting from chromosome abnormalities in the all-1 region |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| WO1994010343A1 (en) * | 1992-10-29 | 1994-05-11 | Thomas Jefferson University | Methods of detecting micrometastasis of prostate cancer |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US7175995B1 (en) * | 1994-10-27 | 2007-02-13 | Thomas Jefferson University | TCL-1 protein and related methods |
| US6242212B1 (en) * | 1996-02-09 | 2001-06-05 | Thomas Jefferson University | Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins |
| US5928884A (en) * | 1996-02-09 | 1999-07-27 | Croce; Carlo M. | FHIT proteins and nucleic acids and methods based thereon |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| WO1998035707A1 (en) * | 1997-02-18 | 1998-08-20 | Thomas Jefferson University | Compositions that bind to pancreatic cancer cells and methods of using the same |
| CA2335315A1 (en) * | 1998-07-20 | 2000-01-27 | Thomas Jefferson University | Nitrilase homologs |
| WO2000005419A1 (en) * | 1998-07-24 | 2000-02-03 | Yeda Research And Development Company Ltd. | Prevention of metastasis with 5-aza-2'-deoxycytidine |
| US7141417B1 (en) * | 1999-02-25 | 2006-11-28 | Thomas Jefferson University | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| EP1276879A4 (en) * | 2000-04-11 | 2004-12-22 | Univ Jefferson | MUIR-TORRE-LIKE SYNDROME IN Fhit-DEFECTIVE MICE |
| US7060811B2 (en) * | 2000-10-13 | 2006-06-13 | Board Of Regents, The University Of Texas System | WWOX: a tumor suppressor gene mutated in multiple cancers |
| US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
| US20040033502A1 (en) * | 2001-03-28 | 2004-02-19 | Amanda Williams | Gene expression profiles in esophageal tissue |
| EP2390328A1 (en) * | 2001-09-28 | 2011-11-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US7371736B2 (en) * | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
| GB0128898D0 (en) * | 2001-12-03 | 2002-01-23 | Biotech Res Ventures Pte Ltd | Materials and methods relating to the stabilization and activation of a tumour suppressor protein |
| WO2003069853A1 (en) * | 2002-02-12 | 2003-08-21 | Nokia Corporation | Method for controlling data transmission, and data transmission system |
| US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| WO2003086445A1 (en) * | 2002-04-08 | 2003-10-23 | Ciphergen Biosystems, Inc. | Serum biomarkers in hepatocellular carcinoma |
| EP1499182B1 (en) * | 2002-04-29 | 2009-10-28 | Thomas Jefferson University | Human chronic lymphocytic leukemia modeled in mouse by targeted tcl1 expression |
| US8119610B2 (en) | 2002-05-31 | 2012-02-21 | The Regents Of The University Of California | Method for efficient RNA interference in mammalian cells |
| EP1530418A4 (en) * | 2002-05-31 | 2005-10-12 | Univ Leland Stanford Junior | METHOD FOR IDENTIFYING AND INSULATING STEM CELLS AND CANCER STAMPS |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| WO2004033659A2 (en) * | 2002-10-11 | 2004-04-22 | Thomas Jefferson University | Novel tumor suppressor gene and compositions and methods for making and using the same |
| US20040152112A1 (en) * | 2002-11-13 | 2004-08-05 | Thomas Jefferson University | Compositions and methods for cancer diagnosis and therapy |
| WO2004071464A2 (en) * | 2003-02-12 | 2004-08-26 | Johns Hopkins University School Of Medicine | Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells |
| CA2518791A1 (en) * | 2003-03-11 | 2004-09-23 | Qlt Usa Inc. | Formulations for cell-schedule dependent anticancer agents |
| US20050069918A1 (en) * | 2003-05-29 | 2005-03-31 | Francois Claret | JAB1 as a prognostic marker and a therapeutic target for human cancer |
| US8106180B2 (en) * | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
| US20050037362A1 (en) * | 2003-08-11 | 2005-02-17 | Eppendorf Array Technologies, S.A. | Detection and quantification of siRNA on microarrays |
| JP2007506425A (ja) * | 2003-09-24 | 2007-03-22 | オンコセラピー・サイエンス株式会社 | 肝細胞癌を診断する方法 |
| CA2554818A1 (en) * | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features |
| US20060134639A1 (en) * | 2004-04-06 | 2006-06-22 | Huffel Christophe V | Method for the determination of cellular transcriptional regulation |
| JP5697297B2 (ja) * | 2004-05-14 | 2015-04-08 | ロゼッタ ジノミクス リミテッド | マイクロｎａｓおよびその使用 |
| EP2290071B1 (en) * | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US7635563B2 (en) * | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
| KR20070058441A (ko) * | 2004-07-01 | 2007-06-08 | 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 면역억제성 엑소솜 |
| US20060037088A1 (en) * | 2004-08-13 | 2006-02-16 | Shulin Li | Gene expression levels as predictors of chemoradiation response of cancer |
| US7893034B2 (en) * | 2004-09-02 | 2011-02-22 | Yale University | Regulation of oncogenes by microRNAs |
| US7642348B2 (en) * | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
| FR2877350B1 (fr) * | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE |
| EP2314688B1 (en) * | 2004-11-12 | 2014-07-16 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| US20060185027A1 (en) * | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| US20070099196A1 (en) * | 2004-12-29 | 2007-05-03 | Sakari Kauppinen | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs |
| US20090123912A1 (en) * | 2005-01-25 | 2009-05-14 | Rosetta Inpharmatics Llc | Methods for quantitating small RNA molecules |
| CN103251946A (zh) * | 2005-02-23 | 2013-08-21 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
| US20070065840A1 (en) * | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
| US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
| AU2006279906B2 (en) * | 2005-08-10 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| US20070092882A1 (en) * | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US7390792B2 (en) * | 2005-12-15 | 2008-06-24 | Board Of Regents, The University Of Texas System | MicroRNA1 therapies |
| ES2524018T3 (es) * | 2006-01-05 | 2014-12-03 | The Ohio State University Research Foundation | Anomalías de la expresión de microARN en tumores pancreáticos endocrinos y acinares |
| WO2007081720A2 (en) * | 2006-01-05 | 2007-07-19 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
| KR101407707B1 (ko) * | 2006-04-03 | 2014-06-19 | 산타리스 팔마 에이/에스 | Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물 |
| AU2007243475B2 (en) * | 2006-04-24 | 2013-02-07 | The Ohio State University Research Foundation | Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in miR155 transgenic mice |
| JP2010510964A (ja) * | 2006-09-19 | 2010-04-08 | アシュラジェン インコーポレイテッド | 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路 |
| CA2663878A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
| AU2007299828C1 (en) * | 2006-09-19 | 2014-07-17 | Interpace Diagnostics, Llc | MicroRNAs differentially expressed in pancreatic diseases and uses thereof |
| US8071292B2 (en) * | 2006-09-19 | 2011-12-06 | The Ohio State University Research Foundation | Leukemia diagnostic methods |
| JP5501766B2 (ja) * | 2006-11-01 | 2014-05-28 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン |
| CN101316935B (zh) * | 2006-11-28 | 2012-02-29 | 博奥生物有限公司 | 一种用于诊断食道癌的芯片 |
| US8293684B2 (en) * | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
| CA2671299A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro rnas |
| CA2671294A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
| AU2007333106A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-20 regulated genes and pathways as targets for therapeutic intervention |
| CN101622350A (zh) * | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为干预治疗靶标的miR-126调控基因和通路 |
| US8034560B2 (en) * | 2007-01-31 | 2011-10-11 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML) |
| ATE553196T1 (de) * | 2007-02-27 | 2012-04-15 | Rosetta Genomics Ltd | Zusammensetzung und verfahren zur modulation von zellproliferation und zelltod |
| EP2126584B1 (en) * | 2007-03-16 | 2012-12-19 | CovalX AG | Direct mass spectrometric analysis of drug candidates targeting protein complexes |
| JP5592251B2 (ja) * | 2007-04-30 | 2014-09-17 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 膵臓癌を正常な膵臓機能および／または慢性膵炎と識別する方法 |
| US20090005336A1 (en) * | 2007-05-08 | 2009-01-01 | Zhiguo Wang | Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions |
| US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| WO2008154098A2 (en) * | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
| US8053186B2 (en) * | 2007-06-15 | 2011-11-08 | The Ohio State University Research Foundation | Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing |
| CA2676113C (en) * | 2007-07-25 | 2014-07-08 | University Of Louisville Research Foundation, Inc. | Exosome-associated microrna as a diagnostic marker |
| US20090061424A1 (en) * | 2007-08-30 | 2009-03-05 | Sigma-Aldrich Company | Universal ligation array for analyzing gene expression or genomic variations |
| US20090123933A1 (en) * | 2007-11-12 | 2009-05-14 | Wake Forest University Health Sciences | Microrna biomarkers in lupus |
| EP2604704B1 (en) * | 2008-02-01 | 2018-10-03 | The General Hospital Corporation | Use of microvesicles in diagnosis and prognosis of brain tumor |
| WO2009108860A2 (en) * | 2008-02-28 | 2009-09-03 | The Ohio University Rasearch Foundation | Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders |
| US20110107440A1 (en) * | 2008-06-04 | 2011-05-05 | Andor Pivarcsi | Skin cancer associated micrornas |
| US20100021734A1 (en) * | 2008-07-22 | 2010-01-28 | Covalent Materials Corporation | Ceramic particles and producing method thereof |
| KR101031305B1 (ko) * | 2008-07-23 | 2011-04-29 | 국립암센터 | 마이크로ｒｎａ-21 저해제를 포함하는 방사선 민감성증진용 조성물 |
| US8728745B2 (en) * | 2008-09-04 | 2014-05-20 | Ventana Medical Sysems, Inc. | Method for prediction of the progression risk of tumors |
| CA2715518A1 (en) * | 2009-09-23 | 2011-03-23 | Wilson Roa | Microrna expression profiles associated with lung cancer |
| CN102844661B (zh) * | 2010-02-11 | 2014-06-25 | 香港理工大学 | 胃癌的生物标志物及其应用 |
-
2008
- 2008-10-10 CA CA2702241A patent/CA2702241A1/en not_active Abandoned
- 2008-10-10 EP EP08838376A patent/EP2212440A4/en not_active Withdrawn
- 2008-10-10 WO PCT/US2008/079482 patent/WO2009049129A1/en not_active Ceased
- 2008-10-10 AU AU2008310704A patent/AU2008310704B2/en not_active Ceased
- 2008-10-10 US US12/682,318 patent/US20100285471A1/en not_active Abandoned
- 2008-10-10 CN CN200880116343.7A patent/CN101861401B/zh not_active Expired - Fee Related
- 2008-10-10 CN CN201410040769.6A patent/CN103937876B/zh not_active Expired - Fee Related
- 2008-10-10 JP JP2010529072A patent/JP5723156B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2702241A1 (en) | 2009-04-16 |
| WO2009049129A1 (en) | 2009-04-16 |
| CN103937876B (zh) | 2016-08-17 |
| EP2212440A4 (en) | 2011-04-06 |
| JP2011501943A (ja) | 2011-01-20 |
| AU2008310704B2 (en) | 2014-03-20 |
| EP2212440A1 (en) | 2010-08-04 |
| CN101861401A (zh) | 2010-10-13 |
| AU2008310704A1 (en) | 2009-04-16 |
| CN101861401B (zh) | 2014-03-12 |
| CN103937876A (zh) | 2014-07-23 |
| US20100285471A1 (en) | 2010-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5723156B2 (ja) | 食道腺癌の診断及び治療のための方法及び組成物 | |
| JP5401460B2 (ja) | ヒト卵巣癌中のマイクロｒｎａシグネチャー | |
| CN103866018B (zh) | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 | |
| CN101627134B (zh) | 用于急性髓细胞白血病（aml）的诊断、预后和治疗的基于微rna的方法和组合物 | |
| EP2152900B1 (en) | Methods for determining hepatocellular carcinoma subtype | |
| JP5743982B2 (ja) | 固形癌の診断及び治療のためのマイクロｒｎａに基づく方法及び組成物 | |
| JP5426383B2 (ja) | 慢性リンパ球性白血病におけるｍｉＲ−２９およびｍｉＲ−１８１によって制御されるＴＣＬ１発現 | |
| US20110152357A1 (en) | Micro-RNA-Based Compositions and Methods for the Diagnosis, Prognosis and Treatment of Multiple Myeloma | |
| CN103589784A (zh) | 用于诊断和治疗结肠癌相关疾病的基于微小rna的方法和组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111007 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111007 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120806 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131029 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140604 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140902 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150226 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150327 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5723156 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |